

Services: Virtual C-Suite

Leverage The Bracken Group's executive-level expertise to support and augment your leadership team when you need it, **for as long as you need it.**

Sometimes you need executive leadership faster than you can possibly find the right fit. When you do, you can turn to The Bracken Group (TBG) to fill the gap. With world-class expertise and acumen, TBG consultants are frequently called on to assist life science companies as . . .

- Chief Executive Officer
- Chief Operating Officer
- Chief Regulatory Affairs Officer
- Chief Medical Officer
- Chief Scientific Officer

In addition to being veterans in these roles, TBG executive consultants are consummate professionals who genuinely invest in the organizations they serve to help them meet their corporate goals and are committed to productive collaboration. They conduct business with every consideration for your existing team.

The Virtual C-Suite Service at TBG was developed at the request of TBG clients and has grown rapidly thanks to their endorsement. Talk with us about how gaps in your senior leadership team or knowledge base might be hindering your organization's progress. We can help.

Work with TBG to ensure . . .

- Temporary gaps in your organization's leadership team won't hold you back
- All the expertise you need for success is present at your table
- Your company has the benefit of top-shelf expertise in Management, Medicine, Regulatory Affairs, and Science

**Are gaps in
your leadership
team or knowledge
base hindering
your organization's
progress?
TBG can help.**



Jim Gilligan,
PhD, MSIB—Chief Executive Officer, Chief Science Officer

Jim is a scientist, entrepreneur, executive, and business development specialist who has co-founded and helped to lead multiple biopharma and biotech companies, including Tarsa Therapeutics, Herborium Inc., and Unigene Labs, where he oversaw the entire spectrum of drug development activities, including pharmacology and preclinical activities, CMC, clinical Phase I-III, as well as US and international regulatory strategies. Download Jim's CV [here](#).



Nick Spring,
DipM, BSc (HONS)—Chief Executive Officer, Chief Operating Officer

Nick is a highly experienced, results-oriented executive with a strong track record of team building, strategic planning, and tactical execution in medical devices, pharma, and biotech organizations. He has held leadership positions with Smith & Nephew, Merck, and Merial, among many others. In 2020, Nick served as founding CEO of ViralClear Pharmaceuticals, a company that was working on a treatment for COVID-19. Download Nick's CV [here](#).



Monica E. Luchi,
MD, FACR, MBA — Chief Medical Officer

Monica has 20 years' experience in the biotech/pharmaceutical industry. Following several years in an academic practice, she held positions of increasing responsibility at Novartis, Incyte, Mesoblast, and Immune Pharmaceuticals in clinical development, translational medicine, and strategic planning, as well as key business development roles. Download Monica's CV [here](#).



Colin G. Miller,
PhD, FIPeM, CSci — Chief Scientific Officer

Co-founder and managing partner of TBG, Colin previously served as Senior Vice President of Medical Affairs at BioClinica and was instrumental in supporting the growth of the company from 35 to more than 1,800 people. Colin started Bona Fide Ltd. (part of the Lunar Corporation) and has also worked at Syntex Pharmaceuticals (now part of Roche) and Procter & Gamble Pharmaceuticals. Download Colin's CV [here](#).



Brad Wyman,
PhD — Chief Scientific Officer

For 10 years, Brad was Head of Functional and Structural Neuroimaging and Director of Imaging, Molecular Medicine at Pfizer. More recently, he was Vice President of Imaging and Clinical Development at ImaginAb, where he was responsible for the development and clinical testing of novel PET tracers. Brad has authored more than 50 peer-reviewed scientific and medical papers. Download Brad's CV [here](#).



Liz Bloss,
DVM — Regulatory Affairs Officer

A co-founder of TBG, Liz has held positions at Sanofi, Novo Nordisk, Bracco, Kyowa Hakko Kirin, and Taiho Oncology. She is an accomplished drug development strategist and a seasoned regulatory leader with a strong track record of delivering IND, NDA, and MAA submissions in multiple therapeutic areas. Download Liz's CV [here](#).